NasdaqGS:PRAXBiotechs
How Investors Are Reacting To Praxis (PRAX) Wider Losses, Fresh NDAs And Multi‑Year Cash Runway
In February 2026, Praxis Precision Medicines reported that its net loss widened to US$88.91 million for the fourth quarter and US$303.27 million for 2025, while basic loss per share from continuing operations rose to US$3.50 for the quarter and US$13.48 for the year.
At the same time, Praxis filed New Drug Applications for ulixacaltamide and relutrigine, signaling a move toward potential commercialization backed by late-stage data and a cash position of about US$1.50 billion that management...